Why Eli Lilly's Zepbound and Mounjaro sales lagged

Eli Lilly'Blockbuster weight-loss drug Zepbound and diabetes drug Mounjaro posted weaker-than-expected sales in the third quarter, although supply of both drugs has largely recovered from widespread shortages in the United States According to the company, the reason is not a…